Objective: To discuss the protective effect of Shenkang injection on residual renal function of patients with uremia after hemodialysis. Method: Eighty-six patients with uremia after hemodialysis were randomly divided into the control group (43 cases) and the observation group (43 cases) by a random number table. In order to control the primary diseases

patients in the control group received hemodialysis

nutritional support

treat anemia

blood glucose and blood pressure (BP) control Based on the treatment of the control group

patients in the observation group added 80 mL Shenkang injection by intravenous infusion once daily. All patients received 6-

4-week periods of treatment separated by 4 weeks without treatment each period. Before and 6-

12-month treatment

residual renal function (RRF) and urine volume were detected. Falling speed of RRF and urine volume were calculated. Incidence rate of privary endpiont (24-hours urine volume≤400 mL) was calculated. Before and after treatment

BP

body weight (BW)

blood urea nitrogen (BUN)

creatinine (Cre)

hemoglobin(Hb)

albumin (Alb) and prealbumin (PA) were observed. Result: RRF and urine volume in the observation group were superior to those in the control group after 6-

12-month treatment (P <0.01). The declining rates of RRF and urine volume in the observation group were lower than those in the control group during 12 months (P <0.01). Levels of systolic BP and diastolic BP in the observation group were lower than those in the control group (P <0.01). The incidence of the primary end point event was 20.9% in the observation

while which was 44.18% in the control group (P <0.05). After therapy

Hb standard in two groups went up

while the result was more obvious in the observation group (P <0.01). Alb and PA levels in the observation group were higher than those in the control group (P <0.01). After treatment

BUN and Scr standard in two groups declined

while the result was lower in the observation group (P <0.01). Conclusion: Shenkang injection has protective effect in treating residual renal function with uremia patients after hemodialysis. It could delay the deterioration speed of the disease and deserves further study.